A Dose-block Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose, First-in-human, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects
Latest Information Update: 07 Dec 2023
At a glance
- Drugs Charis 1000 (Primary)
- Indications Triple negative breast cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Ensol Biosciences
Most Recent Events
- 09 Aug 2023 Status changed from recruiting to completed.
- 09 Aug 2023 Status changed from recruiting to completed.
- 30 Jan 2023 New trial record